Passage Bio (PASG)
(Delayed Data from NSDQ)
$0.71 USD
-0.03 (-4.31%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $0.68 -0.03 (-4.23%) 7:16 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Passage Bio, Inc. (PASG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$6.75 | $13.00 | $3.00 | 812.16% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Passage Bio, Inc. comes to $6.75. The forecasts range from a low of $3.00 to a high of $13.00. The average price target represents an increase of 812.16% from the last closing price of $0.74.
Analyst Price Targets (4 )
Broker Rating
Passage Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PASG.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | Cowen & Co. | Brendan Smith | Strong Buy | Strong Buy |
4/2/2024 | Chardan Capital Markets | Yevgeniya Livshits | Strong Buy | Strong Buy |
3/5/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/4/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
10/16/2023 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $6.75 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.23 |